MX2014003376A - Derivados de acido benzoico como inhibidores eif4e. - Google Patents

Derivados de acido benzoico como inhibidores eif4e.

Info

Publication number
MX2014003376A
MX2014003376A MX2014003376A MX2014003376A MX2014003376A MX 2014003376 A MX2014003376 A MX 2014003376A MX 2014003376 A MX2014003376 A MX 2014003376A MX 2014003376 A MX2014003376 A MX 2014003376A MX 2014003376 A MX2014003376 A MX 2014003376A
Authority
MX
Mexico
Prior art keywords
benzoic acid
acid derivatives
eif4e inhibitors
eif4e
compounds
Prior art date
Application number
MX2014003376A
Other languages
English (en)
Inventor
Paul Gillespie
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014003376A publication Critical patent/MX2014003376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se describen compuestos con la fórmula: (ver Fórmula) en donde R1 y R2 son como se define aquí, que son inhibidores eIF4E útiles en el tratamiento de cánceres. También se describen composiciones que comprenden los compuestos, así como métodos de tratamiento del cáncer que utilizan los compuestos.
MX2014003376A 2011-09-23 2012-09-17 Derivados de acido benzoico como inhibidores eif4e. MX2014003376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538240P 2011-09-23 2011-09-23
PCT/EP2012/068188 WO2013041468A1 (en) 2011-09-23 2012-09-17 Benzoic acid derivatives as eif4e inhibitors

Publications (1)

Publication Number Publication Date
MX2014003376A true MX2014003376A (es) 2014-07-10

Family

ID=46963688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003376A MX2014003376A (es) 2011-09-23 2012-09-17 Derivados de acido benzoico como inhibidores eif4e.

Country Status (11)

Country Link
US (1) US9073881B2 (es)
EP (1) EP2758380B1 (es)
JP (1) JP6010128B2 (es)
KR (1) KR20140064982A (es)
CN (1) CN103958487B (es)
BR (1) BR112014006420A2 (es)
CA (1) CA2847797A1 (es)
ES (1) ES2555286T3 (es)
MX (1) MX2014003376A (es)
RU (1) RU2014114120A (es)
WO (1) WO2013041468A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
JP5598775B2 (ja) 2009-11-02 2014-10-01 ソン，ジャシェン 癌の介入治療および根絶のためのｉｔｅとその類似体を含む医薬組成物
US10081610B2 (en) 2014-09-12 2018-09-25 Ariagen, Inc. Efficient and scalable synthesis of 2-(1′h-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs
UA122061C2 (uk) * 2014-10-08 2020-09-10 Ф. Хоффманн-Ля Рош Аг Похідні спіродіаміну як інгібітори альдостеронсинтази
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
US11459322B2 (en) 2017-11-20 2022-10-04 Ariagen, Inc. Indole compounds and their use
EP3846793B1 (en) * 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
MX2021012543A (es) 2019-04-15 2021-12-10 Ariagen Inc Compuestos de indoles quirales y su uso.
JP2022545987A (ja) * 2019-09-03 2022-11-01 ソバージェン カンパニー，リミテッド ｅＩＦ４Ｅ阻害剤を含むｅＩＦ４Ｅ活性増加に関わる状態の診断または治療用組成物
TW202146393A (zh) * 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
WO2022089514A1 (zh) * 2020-10-28 2022-05-05 上海翰森生物医药科技有限公司 多环类生物调节剂、其制备方法和应用
CN114394934B (zh) * 2022-01-06 2023-06-13 苏州大学 吡唑苯甲酰胺类化合物及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5072023A (en) 1990-02-15 1991-12-10 E. R. Squibb & Sons, Inc. Process for preparing highly substituted phenyls
US6342504B1 (en) 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
US6156776A (en) 1995-06-08 2000-12-05 Yu; Dingwei Tim Diaryl substituted thiazoles useful in the treatment of fungal infections
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US6329528B1 (en) 1998-10-23 2001-12-11 Dow Agrosciences Llc Process for preparing 3-(substituted phenyl)-5-thienyl or furyl)-1,2,4-triazoles and novel intermediates utilized therein
AU2001258784A1 (en) 2000-05-22 2001-12-03 Takeda Chemical Industries Ltd. Tyrosine phosphatase inhibitors
CN100522171C (zh) 2003-09-09 2009-08-05 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂、用于治疗精神病的1-苯甲酰基哌嗪衍生物
WO2005040127A1 (en) 2003-10-27 2005-05-06 Lg Life Sciences Ltd. Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7217723B2 (en) 2004-02-02 2007-05-15 Eisai Co., Ltd. Heterocyclic compound having oxime group
KR101182690B1 (ko) 2004-03-02 2012-09-14 아벤티스 파마슈티칼스 인크. 트립타제 억제제의 제조방법
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1598354A1 (en) 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
SE0401968D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
RU2007109207A (ru) 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
JP5225691B2 (ja) * 2005-01-21 2013-07-03 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ タンパク質合成の調節
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
WO2006137658A1 (en) 2005-06-20 2006-12-28 Dongbu Hitek Co., Ltd. New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same
DE602006016830D1 (de) 2005-09-29 2010-10-21 Sanofi Aventis Derivate von 2-aminthiazolen und 2-aminooxazolen, verfahren zu deren darstellung und deren verwendung als arzneimittel
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
KR20140107671A (ko) 2005-12-30 2014-09-04 머크 샤프 앤드 돔 코포레이션 Ｃｅｔｐ 억제제로서 유용한 1,3-옥사졸리딘-2-온 유도체
EP2007393B1 (en) 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
US20090215778A1 (en) 2007-04-27 2009-08-27 Panacos Pharmaceuticals, Inc. Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives
JP2010529069A (ja) 2007-06-07 2010-08-26 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３アンタゴニストとしてのプロリンアミド誘導体
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
JP5727223B2 (ja) * 2007-10-04 2015-06-03 メルク セローノ ソシエテ アノニム オキサジアゾール・ジアリール化合物
EP2215066A1 (en) 2007-11-01 2010-08-11 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
JP5396578B2 (ja) 2007-11-21 2014-01-22 国立大学法人名古屋大学 光学活性テトラアミノホスホニウム塩、不斉合成反応用触媒、及び光学活性β−ニトロアルコールの製造方法
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2009120826A1 (en) 2008-03-27 2009-10-01 Wyeth 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof
WO2009123753A1 (en) 2008-04-04 2009-10-08 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
JP2011529897A (ja) 2008-07-30 2011-12-15 グラクソスミスクライン エルエルシー 化合物と使用
US8124762B2 (en) 2008-09-05 2012-02-28 Korea Institute Of Science & Technology Diphenyl amine derivatives having luminescence property
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
UY32543A (es) 2009-04-07 2010-11-30 Astrazeneca Ab Análogos de isoxazol-3(2h)-ona como agentes terapéuticos

Also Published As

Publication number Publication date
CN103958487A (zh) 2014-07-30
WO2013041468A1 (en) 2013-03-28
EP2758380A1 (en) 2014-07-30
CN103958487B (zh) 2016-07-13
JP2014526532A (ja) 2014-10-06
KR20140064982A (ko) 2014-05-28
CA2847797A1 (en) 2013-03-28
EP2758380B1 (en) 2015-10-21
ES2555286T3 (es) 2015-12-30
US9073881B2 (en) 2015-07-07
US20130079346A1 (en) 2013-03-28
RU2014114120A (ru) 2015-10-27
JP6010128B2 (ja) 2016-10-19
BR112014006420A2 (pt) 2017-04-11

Similar Documents

Publication Publication Date Title
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
PH12017502141A1 (en) Compounds and their methods of use
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX352975B (es) Piridina y derivados de pirazina.
MX2013008212A (es) Derivados de 7-azaindol.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UA115983C2 (uk) Інгібітори днк-пк
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
PH12015501088A1 (en) Dimeric compounds
MX345127B (es) Derivados de tiazol.
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
EA201490846A1 (ru) Новые производные арилхинолина
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
PH12015501038A1 (en) Inhibitors of iap
MX2016008042A (es) Derivados de imidazopirazinona.
MX2016001536A (es) Derivados de urea de piperidinas.
PH12015500399A1 (en) Azaindolines
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
IN2014DN00123A (es)